Cabaletta Bio Inc.
2.21
0.05 (2.31%)
At close: Jan 14, 2025, 3:59 PM
2.18
-1.36%
After-hours Jan 14, 2025, 05:49 PM EST
undefined%
Bid 2.18
Market Cap 108.02M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -2.16
PE Ratio (ttm) -1.02
Forward PE n/a
Analyst Buy
Ask 2.22
Volume 1,349,544
Avg. Volume (20D) 2,494,337
Open 2.20
Previous Close 2.16
Day's Range 2.11 - 2.25
52-Week Range 1.76 - 26.35
Beta undefined

About CABA

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company's lead product candidate is DSG3-CAART,...

Industry Biotechnology
Sector Healthcare
IPO Date Oct 25, 2019
Employees 136
Stock Exchange NASDAQ
Ticker Symbol CABA

Analyst Forecast

According to 8 analyst ratings, the average rating for CABA stock is "Buy." The 12-month stock price forecast is $27.5, which is an increase of 1144.34% from the latest price.

Buy 75.00%
Hold 25.00%
Sell 0.00%
Stock Forecasts
2 months ago · Source
-19.84%
Cabaletta Bio shares are trading lower after Wells... Unlock content with Pro Subscription
5 months ago · Source
-34.37%
Cabaletta Bio shares are trading lower. The company reported Q2 financial results.